BeiGene, Ltd. (BGNE) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは John V. Oyler.
BGNE を有する IPO日 2016-02-03, 10,600 名の正社員, に上場 NASDAQ Global Select, 時価総額 $20.21B.
BeiGene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for cancer treatment globally. The company's commercial portfolio includes approved drugs such as BRUKINSA for mantle cell lymphoma, Tislelizumab for Hodgkin's lymphoma, and several other therapies for hematologic and solid tumors, complemented by a robust pipeline of clinical-stage candidates targeting various cancer types through innovative mechanisms including BTK inhibitors, PD-1/PD-L1 antibodies, kinase inhibitors, and specialized immunotherapies. BeiGene maintains strategic partnerships with leading pharmaceutical companies including Amgen, Novartis, and Bristol Myers Squibb to strengthen its research and commercialization capabilities. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operates a comprehensive oncology platform serving patients worldwide.
